What is the recommended duration of Macrobid (nitrofurantoin monohydrate/macrocrystals) to treat urinary tract infections (UTIs) in pregnant women?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Duration of Macrobid (Nitrofurantoin) for UTI Treatment in Pregnant Women

The recommended duration of nitrofurantoin monohydrate/macrocrystals (Macrobid) for treating urinary tract infections in pregnant women is 5-7 days at a dose of 100 mg twice daily. 1

Evidence-Based Recommendations

  • The Infectious Diseases Society of America (IDSA) recommends nitrofurantoin monohydrate/macrocrystals at 100 mg twice daily for 5-7 days for uncomplicated urinary tract infections 1
  • This 5-day regimen has been shown to be equivalent to trimethoprim-sulfamethoxazole in terms of clinical and microbiological cure rates 1
  • Clinical cure rates with nitrofurantoin range from 88-93% for uncomplicated UTIs 1
  • Bacterial cure rates with nitrofurantoin range from 81-92% for uncomplicated UTIs 1

Safety in Pregnancy

  • Nitrofurantoin is considered safe during pregnancy, with no evidence of increased risk of fetal abnormalities 2
  • A retrospective analysis of 91 pregnancies in which nitrofurantoin macrocrystals were used showed no significant difference in adverse fetal outcomes compared to the general population 2
  • No abnormal events were considered to be drug-related in pregnant women treated with nitrofurantoin 2

Important Clinical Considerations

  • Nitrofurantoin is contraindicated in patients with creatinine clearance <60 mL/min due to inadequate urinary drug concentrations and increased risk of toxicity 3
  • For pregnant women with reduced renal function, alternative agents should be considered 3
  • The most common side effects of nitrofurantoin include nausea and headache, with adverse event rates ranging from 5.6-34% across studies 1

Follow-up Recommendations

  • A follow-up urine culture should be performed 7 days after completing therapy to confirm cure 4
  • For pregnant women with recurrent UTIs, postcoital prophylaxis with nitrofurantoin macrocrystals (50 mg) has been shown to be highly effective in preventing recurrent infections 5

Clinical Efficacy

  • In a randomized controlled trial, nitrofurantoin demonstrated significant superiority over placebo for both symptomatic improvement and bacteriological cure after just 3 days of treatment 6
  • The Number Needed to Treat (NNT) for bacteriological cure with nitrofurantoin compared to placebo was 1.6 after 3 days of treatment 6

Comparative Efficacy

  • Nitrofurantoin has similar clinical cure rates to ciprofloxacin and trimethoprim-sulfamethoxazole when comparing 7-day regimens for uncomplicated UTIs 1
  • A meta-analysis comparing fosfomycin to nitrofurantoin found no significant differences in clinical cure (RR 0.95% CI 0.81-1.12) or microbiological cure (RR 0.96,95% CI 0.84-1.08) 7

Remember that treating UTIs promptly and effectively during pregnancy is crucial to prevent progression to pyelonephritis, which can increase the risk of preterm labor and other pregnancy complications.

References

Guideline

Nitrofurantoin Dosing for Uncomplicated UTI

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Nitrofurantoin Dosing Considerations in Adults with UTIs

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Recommended treatment for urinary tract infection in pregnancy.

The Annals of pharmacotherapy, 1994

Research

Effective prophylaxis for recurrent urinary tract infections during pregnancy.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1992

Research

Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women.

The British journal of general practice : the journal of the Royal College of General Practitioners, 2002

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.